Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 3/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20832054 | 0.88 | GPR119 (0.44) | ATRGPR119ALDH1A1LMNA | |
| SCHEMBL20818165 | 0.86 | RXRA (0.34) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL20817846 | 0.80 | CYP4F2 (0.37) | ATRCYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL20817847 | 0.80 | CYP4F2 (0.37) | ATRCYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL20817776 | 0.74 | RXRA (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL20832056 | 0.74 | SMARCA2 (0.41) | ATRGPR119LMNA | |
| SCHEMBL20831547 | 0.74 | ATR (0.34) | IDH1ATRCYP4F2CYP4A11 | |
| SCHEMBL20818575 | 0.73 | TRPC5 (0.34) | ATRCYP4F2CYP4A11CHRM4KCNH2 | |
| SCHEMBL23489835 | 0.73 | CYP4F2 (0.36) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL20831759 | 0.72 | ATR (0.33) | IDH1ATRCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | IDH1 1443/4885GRM1 2269/4885ATR 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.